Why Emergent BioSolutions Stock Fell Today
Shares of Emergent BioSolutions (NYSE: EBS) were trading 3.8% lower as of 3:01 p.m. EDT on Tuesday. The decline came after the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) called for a pause in the administration of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.
Emergent BioSolutions contracted to manufacture J&J's COVID-19 vaccine. Therefore, any long-term issues with the vaccine could potentially hurt Emergent.
Image source: Getty Images.
Source Fool.com
